

<b>APPLICANT</b> (stamp or sticker acceptable)	<b>PATIENT NHI:</b> .....	<b>REFERRER</b> Reg No: .....
Reg No: .....	First Names: .....	First Names: .....
Name: .....	Surname: .....	Surname: .....
Address: .....	DOB: .....	Address: .....
.....	Address: .....	.....
.....	.....	.....
Fax Number: .....	.....	Fax Number: .....

**Budesonide - Cap 3 mg Controlled Release**

**Initial application — Crohn's disease**

Applications from any relevant practitioner. Approvals valid for 6 months.

**Prerequisites**(tick boxes where appropriate)

- ☐ Mild to moderate ileal, ileocaecal or proximal Crohn's disease
- and
- ☐ Diabetes
- or
- ☐ Cushingoid habitus
- or
- ☐ Osteoporosis where there is significant risk of fracture
- or
- ☐ Severe acne following treatment with conventional corticosteroid therapy
- or
- ☐ History of severe psychiatric problems associated with corticosteroid treatment
- or
- ☐ History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high
- or
- ☐ Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated)

**Initial application — collagenous and lymphocytic colitis (microscopic colitis)**

Applications from any relevant practitioner. Approvals valid for 6 months.

**Prerequisites**(tick box where appropriate)

- ☐ Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies

**Initial application — gut Graft versus Host disease**

Applications from any relevant practitioner. Approvals valid for 6 months.

**Prerequisites**(tick box where appropriate)

- ☐ Patient has a gut Graft versus Host disease following allogenic bone marrow transplantation\*

Note: Indication marked with \* is an unapproved indication.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ..... Date: .....

Post application to Ministry of Health, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)

<b>APPLICANT</b> (stamp or sticker acceptable)	<b>PATIENT</b> NHI: .....	<b>REFERRER</b> Reg No: .....
Reg No: .....	First Names: .....	First Names: .....
Name: .....	Surname: .....	Surname: .....
Address: .....	DOB: .....	Address: .....
.....	Address: .....	.....
.....	.....	.....
Fax Number: .....	.....	Fax Number: .....

**Budesonide - Cap 3 mg Controlled Release** - continued

**Initial application — non-cirrhotic autoimmune hepatitis**

Applications from any relevant practitioner. Approvals valid for 6 months.

**Prerequisites**(tick boxes where appropriate)

- ☐ Patient has autoimmune hepatitis\*
- and
- ☐ Patient does not have cirrhosis
- and
- ☐ Diabetes

or

☐ Cushingoid habitus

or

☐ Osteoporosis where there is significant risk of fracture

or

☐ Severe acne following treatment with conventional corticosteroid therapy

or

☐ History of severe psychiatric problems associated with corticosteroid treatment

or

☐ History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high

or

☐ Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated)

or

☐ Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth)

Note: Indication marked with \* is an unapproved indication.

**Renewal**

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 6 months.

**Prerequisites**(tick box where appropriate)

- ☐ The treatment remains appropriate and the patient is benefiting from treatment

**Renewal — non-cirrhotic autoimmune hepatitis**

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 6 months.

**Prerequisites**(tick box where appropriate)

- ☐ The treatment remains appropriate and the patient is benefiting from treatment

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ..... Date: .....

Post application to Ministry of Health, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)